MET alterations in advanced non-small cell lung cancer

被引：10
作者：
Sakamoto, Mandy [1 ]
Patil, Tejas [1 ,2 ]
机构：
[1] Dept Med, Div Med Oncol, Aurora, CO USA
[2] Univ Colorado, Canc Ctr, 1665 Aurora Court,MS F704, Aurora, CO 80045 USA
来源：
LUNG CANCER | 2023年 / 178卷
关键词：
NSCLC; MET alterations; MET amplification; MET overexpression; HEPATOCYTE GROWTH-FACTOR; EXON; 14; MUTATIONS; GENE COPY NUMBER; PREVIOUSLY TREATED PATIENTS; TYROSINE KINASE INHIBITORS; TIVANTINIB ARQ 197; PHASE-II; C-MET; ACQUIRED-RESISTANCE; SKIPPING ALTERATIONS;
D O I：
10.1016/j.lungcan.2023.02.018
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Targeting the MET pathway in advanced NSCLC has been of particular interest due to its role as both a primary oncogenic driver and secondary oncogenic driver of acquired resistance. Activation of the MET pathway can occur through several mechanisms, which can complicate the diagnostic and treatment approach. Recently, several MET-directed therapies have been developed with promising results. In this narrative review, we sum-marize the biology and mechanism of MET as a clinically relevant driver mutation, distinct MET alterations including diagnostic challenges, significance in the setting of acquired resistance, and novel treatment strategies in advanced NSCLC.
引用
收藏
页码：254 / 268
页数：15
相关论文
共 50 条
  • [1] MET alterations in advanced non-small cell lung cancer
    Chagas, Gabriel Cavalcante Lima
    Rangel, Amanda Ribeiro
    El Osta, Badi
    CURRENT PROBLEMS IN CANCER, 2024, 49
  • [2] MET alterations and their impact on the future of non-small cell lung cancer (NSCLC) targeted therapies
    Lee, Matthew
    Jain, Prantesh
    Wang, Feng
    Ma, Patrick C.
    Borczuk, Alain
    Halmos, Balazs
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2021, 25 (04) : 249 - 268
  • [3] Emerging MET tyrosine kinase inhibitors for the treatment of non-small cell lung cancer
    Fujino, Toshio
    Suda, Kenichi
    Mitsudomi, Tetsuya
    EXPERT OPINION ON EMERGING DRUGS, 2020, 25 (03) : 229 - 249
  • [4] MET in Non-Small-Cell Lung Cancer (NSCLC): Cross 'a Long and Winding Road' Looking for a Target
    Spitaleri, Gianluca
    Aliaga, Pamela Trillo
    Attili, Ilaria
    Del Signore, Ester
    Corvaja, Carla
    Corti, Chiara
    Uliano, Jacopo
    Passaro, Antonio
    de Marinis, Filippo
    CANCERS, 2023, 15 (19)
  • [5] Management and Treatment of Non-small Cell Lung Cancer with MET Alteration and Mechanisms of Resistance
    Moiseenko, Fedor
    Bogdanov, Alexey
    Egorenkov, Vitaliy
    Volkov, Nikita
    Moiseyenko, Vladimir
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2022, 23 (12) : 1664 - 1698
  • [6] Targeting un-MET needs in advanced non-small cell lung cancer
    Coleman, Niamh
    Harbery, Alice
    Heuss, Sara
    Vivanco, Igor
    Popat, Sanjay
    LUNG CANCER, 2022, 164 : 56 - 68
  • [7] Capmatinib for the treatment of non-small cell lung cancer
    Vansteenkiste, Johan Filip
    Van de Kerkhove, Charlotte
    Wauters, Els
    Van Mol, Pierre
    EXPERT REVIEW OF ANTICANCER THERAPY, 2019, 19 (08) : 659 - 671
  • [8] Novel Therapies for Metastatic Non-Small Cell Lung Cancer with MET Exon 14 Alterations: A Spotlight on Capmatinib
    Tan, Aaron C.
    Loh, Tracy J.
    Kwang, Xue Lin
    San Tan, Gek
    Lim, Kiat Hon
    Tan, Daniel S. W.
    LUNG CANCER-TARGETS AND THERAPY, 2021, 12 : 11 - 20
  • [9] Efficacy and safety analysis of immunotherapy in non-small cell lung cancer patients with MET alterations
    Wang, Yanhua
    Wei, Jingwen
    Xu, Manyi
    Xiang, Jing
    Shao, Keda
    Hao, Yue
    Song, Zhengbo
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2024, 26 (10) : 2503 - 2512
  • [10] Progress on treatment of MET signaling pathway in non-small cell lung cancer
    Yu, Xiaoqing
    Yu, Sizhe
    Fan, Yun
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2020, 25 (08) : 1450 - 1458
12345